AstraZeneca PLC (AZN)

Basic

  • Market Cap

    £157.01B

  • EV

    £177.05B

  • Shares Out

    1,549.93M

  • Revenue

    $44.99B

  • Employees

    83,500

Margins

  • Gross

    89.17%

  • EBITDA

    41.57%

  • Operating

    31.22%

  • Pre-Tax

    15.07%

  • Net

    13.1%

  • FCF

    20.35%

Returns (5Yr Avg)

  • ROA

    3.72%

  • ROE

    10.71%

  • ROCE

    8.11%

  • ROIC

    5.01%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • EV/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    £165.55

  • P/E

  • EV/Sales

  • EV/EBITDA

  • EV/FCF

Per Share

  • Rev

    $29.05

  • Earnings (Dil)

    $3.78

  • FCF

    $5.87

  • Book Value

    $24.01

Growth (CAGR)

  • Rev 3Yr

    20.26%

  • Rev 5Yr

    15.97%

  • Rev 10Yr

    5.58%

  • Dil EPS 3Yr

    25.77%

  • Dil EPS 5Yr

    14.63%

  • Dil EPS 10Yr

    0.3%

  • Rev Fwd 2Yr

    6.57%

  • EBITDA Fwd 2Yr

    39.7%

  • EPS Fwd 2Yr

    10.7%

  • EPS LT Growth Est

    13.45%

Dividends

  • Yield

  • Payout

    76.18%

  • DPS

    $2.9

  • DPS Growth 3Yr

    1.18%

  • DPS Growth 5Yr

    0.7%

  • DPS Growth 10Yr

    0.35%

  • DPS Growth Fwd 2Yr

    4.44%

Select a metric from the list below to chart it

Dec '13
Dec '15
Dec '17
Dec '19
Dec '21
LTM

Revenues

22,090.0

24,384.0

26,617.0

37,417.0

44,351.0

44,994.0

Other Revenues, Total

Total Revenues

22,090.0

24,384.0

26,617.0

37,417.0

44,351.0

44,994.0

Total Revenues % Chg.

-1.7%

10.4%

9.2%

40.6%

18.5%

-0.4%

Cost of Goods Sold, Total

4,504.0

4,848.0

5,246.0

9,799.0

8,619.0

4,873.0

Gross Profit

17,586.0

19,536.0

21,371.0

27,618.0

35,732.0

40,121.0

Selling General & Admin Expenses, Total

10,822.0

11,438.0

11,586.0

14,461.0

17,471.0

17,202.0

R&D Expenses

5,299.0

5,349.0

5,901.0

8,021.0

9,529.0

9,800.0

Other Operating Expenses

-266.0

-319.0

-486.0

-207.0

-231.0

-927.0

Other Operating Expenses, Total

15,855.0

16,468.0

17,001.0

22,275.0

26,769.0

26,075.0

Operating Income

1,731.0

3,068.0

4,370.0

5,343.0

8,963.0

14,046.0

Interest Expense, Total

-744.0

-780.0

-738.0

-776.0

-917.0

-1,112.0

Interest And Investment Income

132.0

145.0

77.0

43.0

81.0

267.0

Net Interest Expenses

-612.0

-635.0

-661.0

-733.0

-836.0

-845.0

Income (Loss) On Equity Invest.

-113.0

-116.0

-27.0

-64.0

-5.0

-13.0

Currency Exchange Gains (Loss)

-51.0

-30.0

-34.0

-20.0

-16.0

-16.0

Other Non Operating Income (Expenses)

-566.0

-542.0

-487.0

-478.0

-370.0

-370.0

EBT, Excl. Unusual Items

389.0

1,745.0

3,161.0

4,048.0

7,736.0

12,802.0

Restructuring Charges

-697.0

-347.0

-251.0

-1,283.0

-717.0

-1,069.0

Merger & Related Restructuring Charges

-2,441.0

-3,571.0

-3,665.0

Gain (Loss) On Sale Of Investments

776.0

Gain (Loss) On Sale Of Assets

1,877.0

1,222.0

1,055.0

509.0

216.0

396.0

Asset Writedown

-683.0

-1,036.0

-252.0

-2,069.0

-241.0

-573.0

Legal Settlements

593.0

-610.0

9.0

-48.0

-789.0

-949.0

Other Unusual Items

514.0

574.0

194.0

243.0

-133.0

-162.0

EBT, Incl. Unusual Items

1,993.0

1,548.0

3,916.0

-265.0

2,501.0

6,780.0

Income Tax Expense

-57.0

321.0

772.0

-380.0

-792.0

876.0

Earnings From Continuing Operations

2,050.0

1,227.0

3,144.0

115.0

3,293.0

5,904.0

Minority Interest

105.0

108.0

52.0

-3.0

-5.0

-8.0

Net Income

2,155.0

1,335.0

3,196.0

112.0

3,288.0

5,896.0

Net Income to Common Incl Extra Items

2,155.0

1,335.0

3,196.0

112.0

3,288.0

5,896.0

Net Income to Common Excl. Extra Items

2,155.0

1,335.0

3,196.0

112.0

3,288.0

5,896.0

Total Shares Outstanding

1,267.0

1,312.1

1,312.7

1,549.4

1,549.8

1,549.0

Weighted Avg. Shares Outstanding

1,267.0

1,301.0

1,312.0

1,418.0

1,548.0

1,548.8

Weighted Avg. Shares Outstanding Dil

1,267.0

1,301.0

1,313.0

1,427.0

1,560.0

1,560.0

EPS

1.7

1.0

2.4

0.1

2.1

3.8

EPS Diluted

1.7

1.0

2.4

0.1

2.1

3.8

EBITDA

4,462.0

5,575.0

6,990.0

9,147.0

13,895.0

18,706.0